CN1103766C - 新的紫杉化合物、其制备方法及其药物组合物 - Google Patents

新的紫杉化合物、其制备方法及其药物组合物 Download PDF

Info

Publication number
CN1103766C
CN1103766C CN96199168A CN96199168A CN1103766C CN 1103766 C CN1103766 C CN 1103766C CN 96199168 A CN96199168 A CN 96199168A CN 96199168 A CN96199168 A CN 96199168A CN 1103766 C CN1103766 C CN 1103766C
Authority
CN
China
Prior art keywords
group
hydrogen atom
general formula
compound
bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN96199168A
Other languages
English (en)
Chinese (zh)
Other versions
CN1205697A (zh
Inventor
H·伯查德
A·考墨科恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Publication of CN1205697A publication Critical patent/CN1205697A/zh
Application granted granted Critical
Publication of CN1103766C publication Critical patent/CN1103766C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN96199168A 1995-12-22 1996-12-19 新的紫杉化合物、其制备方法及其药物组合物 Expired - Fee Related CN1103766C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9515379A FR2742751B1 (fr) 1995-12-22 1995-12-22 Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR95/15379 1995-12-22

Publications (2)

Publication Number Publication Date
CN1205697A CN1205697A (zh) 1999-01-20
CN1103766C true CN1103766C (zh) 2003-03-26

Family

ID=9485871

Family Applications (1)

Application Number Title Priority Date Filing Date
CN96199168A Expired - Fee Related CN1103766C (zh) 1995-12-22 1996-12-19 新的紫杉化合物、其制备方法及其药物组合物

Country Status (40)

Country Link
US (1) US5728849A (enExample)
EP (1) EP0876362B1 (enExample)
JP (1) JP3953106B2 (enExample)
KR (1) KR100500351B1 (enExample)
CN (1) CN1103766C (enExample)
AR (1) AR005197A1 (enExample)
AT (1) ATE250593T1 (enExample)
AU (1) AU712597B2 (enExample)
BG (1) BG63204B1 (enExample)
BR (1) BR9612135A (enExample)
CA (1) CA2238884C (enExample)
CO (1) CO4520184A1 (enExample)
CZ (1) CZ294972B6 (enExample)
DE (1) DE69630145T2 (enExample)
DK (1) DK0876362T3 (enExample)
DZ (1) DZ2149A1 (enExample)
EA (1) EA001533B1 (enExample)
ES (1) ES2202490T3 (enExample)
FR (1) FR2742751B1 (enExample)
HU (1) HU225032B1 (enExample)
IL (1) IL124994A (enExample)
IN (4) IN186768B (enExample)
MA (1) MA26412A1 (enExample)
MX (1) MX9804688A (enExample)
MY (1) MY113934A (enExample)
NO (1) NO317358B1 (enExample)
NZ (1) NZ324337A (enExample)
OA (1) OA10700A (enExample)
PE (1) PE25198A1 (enExample)
PL (1) PL189311B1 (enExample)
PT (1) PT876362E (enExample)
RO (1) RO116194B1 (enExample)
SK (1) SK282835B6 (enExample)
TN (1) TNSN96169A1 (enExample)
TR (1) TR199801179T2 (enExample)
TW (1) TW371659B (enExample)
UA (1) UA48205C2 (enExample)
UY (1) UY24386A1 (enExample)
WO (1) WO1997023473A1 (enExample)
ZA (1) ZA9610737B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9920548D0 (en) * 1999-08-31 1999-11-03 Rhone Poulenc Rorer Sa Treatment of hepatocellular carcinoma
CA2368151A1 (en) 2000-02-02 2001-08-09 Florida State University Research Foundation, Inc. C10 carbonate substituted taxanes as antitumor agents
ES2326911T3 (es) * 2001-02-24 2009-10-21 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Derivados de xantina para uso como medicamentos, asi como su procedimiento de preparacion.
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20080107721A1 (en) * 2003-05-20 2008-05-08 Jonathan Lewis Combination Chemotherapy Comprising A Liposomal Platinum Complex
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1669358A1 (en) 2004-12-07 2006-06-14 Aventis Pharma S.A. Cytotoxic agents comprising new taxanes
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
US20080207743A1 (en) * 2007-02-28 2008-08-28 Rodger Lamb Biologically Active Taxane Analogs and Methods of Treatment
CN101784278A (zh) * 2007-08-17 2010-07-21 贝林格尔.英格海姆国际有限公司 用于治疗fab-相关的疾病的嘌呤衍生物
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
AU2009281122C1 (en) * 2008-08-15 2016-04-21 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
MX2011006713A (es) 2008-12-23 2011-07-13 Boehringer Ingelheim Int Formas salinas de compuesto organico.
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
KR20120107080A (ko) 2009-11-27 2012-09-28 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CN107961377B (zh) 2010-05-05 2022-11-22 勃林格殷格翰国际有限公司 组合疗法
KR20130093012A (ko) 2010-06-24 2013-08-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CA2891280C (en) 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
FR3010839B1 (fr) * 2013-09-17 2017-04-21 Schneider Electric Ind Sas Dispositif de raccordement electrique d'au moins un conducteur dans une borne appartenant a un appareil electrique
WO2015127685A1 (en) 2014-02-28 2015-09-03 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Dpp−4阻害薬の医学的使用
EP3319936B1 (en) 2015-07-12 2025-12-17 Hangzhou Dac Biotech Co., Ltd. Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
MX390363B (es) 2016-06-10 2025-03-20 Boehringer Ingelheim Int Combinacion de linagliptina y metformina
JP7138350B2 (ja) 2016-11-14 2022-09-16 ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ. 共役連結体、該連結体を含有する細胞結合分子-薬物共役体、並びに該共役体及び連結体の使用及び製造方法
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021173A1 (en) * 1992-04-17 1993-10-28 Abbott Laboratories Taxol derivatives
CN1095377A (zh) * 1992-12-15 1994-11-23 厄普约翰公司 7-卤代和7β,8β-亚甲基-紫杉醇,抗肿瘤用途以及含其药物组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2017724C1 (ru) * 1990-07-12 1994-08-15 Дзе Юниверсити оф Канзас Способ получения производных таксола
US5059699A (en) * 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
FR2678930B1 (fr) * 1991-07-10 1995-01-13 Rhone Poulenc Rorer Sa Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii.
RU2059631C1 (ru) * 1991-11-29 1996-05-10 Дзе Юниверсити оф Канзас Производные таксола и фармацевтическая композиция, обладающая противоопухолевой активностью
US5254580A (en) * 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021173A1 (en) * 1992-04-17 1993-10-28 Abbott Laboratories Taxol derivatives
CN1095377A (zh) * 1992-12-15 1994-11-23 厄普约翰公司 7-卤代和7β,8β-亚甲基-紫杉醇,抗肿瘤用途以及含其药物组合物

Also Published As

Publication number Publication date
HUP9904046A3 (en) 2001-08-28
EA199800588A1 (ru) 1998-12-24
TNSN96169A1 (fr) 2005-03-15
HU225032B1 (en) 2006-05-29
ES2202490T3 (es) 2004-04-01
AU1180997A (en) 1997-07-17
DE69630145T2 (de) 2004-07-15
DK0876362T3 (da) 2004-02-02
TR199801179T2 (xx) 1998-10-21
HUP9904046A1 (hu) 2001-04-28
PE25198A1 (es) 1998-05-10
AU712597B2 (en) 1999-11-11
CZ196198A3 (cs) 1998-09-16
US5728849A (en) 1998-03-17
UA48205C2 (uk) 2002-08-15
ZA9610737B (en) 1997-06-27
MX9804688A (es) 1998-10-31
DE69630145D1 (de) 2003-10-30
IL124994A0 (en) 1999-01-26
PL189311B1 (pl) 2005-07-29
SK85398A3 (en) 1998-11-04
JP3953106B2 (ja) 2007-08-08
OA10700A (fr) 2002-11-27
MY113934A (en) 2002-06-29
UY24386A1 (es) 2001-08-27
EP0876362A1 (fr) 1998-11-11
ATE250593T1 (de) 2003-10-15
JP2000502671A (ja) 2000-03-07
NO317358B1 (no) 2004-10-18
FR2742751B1 (fr) 1998-01-30
FR2742751A1 (fr) 1997-06-27
CZ294972B6 (cs) 2005-04-13
BG102569A (en) 1999-04-30
NO982580L (no) 1998-06-05
RO116194B1 (ro) 2000-11-30
EA001533B1 (ru) 2001-04-23
TW371659B (en) 1999-10-11
NZ324337A (en) 2000-03-27
BR9612135A (pt) 1999-07-13
WO1997023473A1 (fr) 1997-07-03
CN1205697A (zh) 1999-01-20
BG63204B1 (bg) 2001-06-29
KR100500351B1 (ko) 2005-12-21
KR19990076680A (ko) 1999-10-15
CO4520184A1 (es) 1997-10-15
IN186768B (enExample) 2001-11-03
PL327405A1 (en) 1998-12-07
HK1017895A1 (en) 1999-12-03
EP0876362B1 (fr) 2003-09-24
NO982580D0 (no) 1998-06-05
IN188469B (enExample) 2002-09-28
CA2238884C (fr) 2007-02-06
MA26412A1 (fr) 2004-12-20
CA2238884A1 (fr) 1997-07-03
AR005197A1 (es) 1999-04-14
IL124994A (en) 2000-12-06
DZ2149A1 (fr) 2002-10-23
IN188680B (enExample) 2002-10-26
SK282835B6 (sk) 2002-12-03
IN188470B (enExample) 2002-09-28
PT876362E (pt) 2004-02-27

Similar Documents

Publication Publication Date Title
CN1103766C (zh) 新的紫杉化合物、其制备方法及其药物组合物
CN1055467C (zh) 紫杉类化合物、其制备以及含有它们的药物组合物
US6331635B1 (en) Taxoids, their preparation and pharmaceutical compositions containing them
CN1073105C (zh) 具有抗肿瘤活性的半合成紫杉烷
JPH05239044A (ja) 新規なアルコキシ置換されたタキサン及びそれらを含有する薬剤組成物
AU715228B2 (en) Taxoids, preparation thereof and pharmaceutical compositions containing same
US6593482B2 (en) Methods for preparing new taxoids and pharmaceutical compositions containing them
CN1179777A (zh) 新的紫杉化合物,其制备方法及其药物组合物
CZ133696A3 (en) Novel taxoids, process of their preparation and pharmaceutical composition containing thereof
US6372780B2 (en) Methods of treating cell lines expressing multidrug resistance P-glycoprotein
CN1150422A (zh) 新的紫杉化合物、其制备方法和药物组合物
JPH10500979A (ja) 新規タキソイド類、その製造およびそれらを含む製薬学的組成物
US6156789A (en) Method for treating abnormal cell proliferation in the brain
JP3431155B2 (ja) 10−デスアセトキシバッカチンiiiの製法
HK1017895B (en) Novel taxoids, preparation thereof and pharmaceutical compositions containing same
US20020010348A1 (en) Methods for preparing new taxoids and pharmaceutical compositions containing them
EP0764156A1 (fr) Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: AVENTIS PHARMA S.A.

Free format text: FORMER NAME OR ADDRESS: RHONE-POULENC RORER S.A.

CP03 Change of name, title or address

Address after: French Anthony

Patentee after: Awentis Pharmaceutical S. A.

Address before: French Anthony

Patentee before: Rhone-Poulenc Rorer S. A.

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20030326

Termination date: 20121219